The codon 72 polymorphism of p53 influences cell fate following nutrient deprivation

References

• Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Na Rev Cancer 2009; 9:749-58; PMID:19776744; https://doi.org/10.1038/nrc2723
   PubMed Web of Science ®Google Scholar
• Murphy ME. Polymorphic variants in the p53 pathway. Cell Death Differ 2006; 13:916-20; PMID:16557270; https://doi.org/10.1038/sj.cdd.4401907
   PubMed Web of Science ®Google Scholar
• Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Na Rev Cancer 2009; 9:95-107; PMID:19165225; https://doi.org/10.1038/nrc2584
   PubMed Web of Science ®Google Scholar
• Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006; 66:5104-10; PMID:16707433; https://doi.org/10.1158/0008-5472.CAN-06-0180
   PubMed Web of Science ®Google Scholar
• Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119:591-602; PMID:15550242; https://doi.org/10.1016/j.cell.2004.11.022
   PubMed Web of Science ®Google Scholar
• Jennis M, Kung CP, Basu S, Budina-Kolomets A, Leu JI, Khaku S, Scott JP, Cai KQ, Campbell MR, Porter DK, et al. An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev 2016; 30:918-30; PMID:27034505; https://doi.org/10.1101/gad.275891.115
   PubMed Web of Science ®Google Scholar
• Basu S, Barnoud T, Kung CP, Reiss M, Murphy ME. The African-specific S47 polymorphism of p53 alters chemosensitivity. Cell cycle 2016; 15:2557-60; PMID:27484708; https://doi.org/10.1080/15384101.2016.1215390
   PubMed Web of Science ®Google Scholar
• Murphy ME, Liu S, Yao S, Huo D, et al. A functionally significant SNP in TP53 and breast cancer risk in African American women. NPJ Breast Cancer 2017; 3:5; PMID:28232952; https://doi.org/:10.1038/s41523-017-0007-9
   PubMed Web of Science ®Google Scholar
• Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999; 19:1092-100; PMID:9891044; https://doi.org/10.1128/MCB.19.2.1092
   PubMed Web of Science ®Google Scholar
• Dumont P, Leu JI, Della Pietra AC, 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33:357-65; PMID:12567188; https://doi.org/10.1038/ng1093
   PubMed Web of Science ®Google Scholar
• Frank AK, Leu JI, Zhou Y, Devarajan K, Nedelko T, Klein-Szanto A, Hollstein M, Murphy ME. The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation. Mol Cell Biol 2011; 31:1201-13; PMID:21245379; https://doi.org/10.1128/MCB.01136-10
   PubMed Web of Science ®Google Scholar
• Kung CP, Leu JI, Basu S, Khaku S, Anokye-Danso F, Liu Q, George DL, Ahima RS, Murphy ME. The P72R Polymorphism of p53 Predisposes to Obesity and Metabolic Dysfunction. Cell Rep 2016; 14:2413-25; PMID:26947067; https://doi.org/10.1016/j.celrep.2016.02.037
   PubMed Web of Science ®Google Scholar
• Leu JI, Murphy ME, George DL. The p53 Codon 72 polymorphism modifies the cellular response to inflammatory challenge in the liver. J Liver 2013; 2:117; PMID:23991369; https://doi.org/10.4172/2167-0889.1000117
   PubMedGoogle Scholar
• Kung CP, Khaku S, Jennis M, Zhou Y, Murphy ME. Identification of TRIML2, a Novel p53 target, that enhances p53-SUMOylation and regulates the transactivation of pro-apoptotic genes. Mol Cancer Res 2015 Feb; 13(2):250-62; PMID:25256710; https://doi.org/10.1158/1541-7786.MCR-14-0385
   PubMed Web of Science ®Google Scholar
• Feng Z, Zhang C, Kang HJ, Sun Y, Wang H, Naqvi A, Frank AK, Rosenwaks Z, Murphy ME, Levine AJ, et al. Regulation of female reproduction by p53 and its family members. FASEB J 2011; 25:2245-55; PMID:21402718; https://doi.org/10.1096/fj.10-180166
   PubMed Web of Science ®Google Scholar
• Sjalander A, Birgander R, Kivela A, Beckman G. p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered 1995; 45:144-9; PMID:7615299; https://doi.org/10.1159/000154275
   PubMed Web of Science ®Google Scholar
• Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, Beckman L. Is p53 polymorphism maintained by natural selection? Hum Hered 1994; 44:266-70; PMID:7927355; https://doi.org/10.1159/000154228
   PubMed Web of Science ®Google Scholar
• Burgdorf KS, Grarup N, Justesen JM, Harder MN, Witte DR, Jorgensen T, Sandbæk A, Lauritzen T, Madsbad S, Hansen T, et al. Studies of the association of Arg72Pro of tumor suppressor protein p53 with type 2 diabetes in a combined analysis of 55,521 Europeans. PloS one 2011; 6:e15813; PMID:21283750; https://doi.org/10.1371/journal.pone.0015813
   PubMed Web of Science ®Google Scholar
• Gaulton KJ, Willer CJ, Li Y, Scott LJ, Conneely KN, Jackson AU, Duren WL, Chines PS, Narisu N, Bonnycastle LL, et al. Comprehensive association study of type 2 diabetes and related quantitative traits with 222 candidate genes. Diabetes 2008; 57:3136-44; PMID:18678618; https://doi.org/10.2337/db07-1731
   PubMed Web of Science ®Google Scholar
• Gloria-Bottini F, Banci M, Saccucci P, Magrini A, Bottini E. Is there a role of p53 codon 72 polymorphism in the susceptibility to type 2 diabetes in overweight subjects? A study in patients with cardiovascular diseases. Diabetes Res Clin Pract 2011; 91:e64-7; PMID:21146884; https://doi.org/10.1016/j.diabres.2010.11.031
   PubMed Web of Science ®Google Scholar
• Reiling E, Lyssenko V, Boer JM, Imholz S, Verschuren WM, Isomaa B, Tuomi T, Groop L, Dollé ME. Codon 72 polymorphism (rs1042522) of TP53 is associated with changes in diastolic blood pressure over time. Eur J Hum Genet 2012; 20:696-700; PMID:22189267; https://doi.org/10.1038/ejhg.2011.240
   PubMed Web of Science ®Google Scholar
• Reinbold M, Luo JL, Nedelko T, Jerchow B, Murphy ME, Whibley C, Wei Q, Hollstein M. Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72. Oncogene 2008; 27:2788-94; PMID:17998932; https://doi.org/10.1038/sj.onc.1210932
   PubMed Web of Science ®Google Scholar
• Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005; 18:283-93; PMID:15866171; https://doi.org/10.1016/j.molcel.2005.03.027
   PubMed Web of Science ®Google Scholar
• Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67:6745-52; PMID:17638885; https://doi.org/10.1158/0008-5472.CAN-06-4447
   PubMed Web of Science ®Google Scholar
• Shi H, Tan SJ, Zhong H, Hu W, Levine A, Xiao CJ, Peng Y, Qi XB, Shou WH, Ma RL, et al. Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia. Am J Hum Genet 2009; 84:534-41; PMID:19344876; https://doi.org/10.1016/j.ajhg.2009.03.009
   PubMed Web of Science ®Google Scholar
• Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 2004; 6:443-50; PMID:15077116; https://doi.org/10.1038/ncb1123
   PubMed Web of Science ®Google Scholar
• Carvajal LA, Manfredi JJ. Another fork in the road–life or death decisions by the tumour suppressor p53. EMBO Rep 2013; 14:414-21; PMID:23588418; https://doi.org/10.1038/embor.2013.25
   PubMed Web of Science ®Google Scholar
• Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282:1497-501; PMID:9822382; https://doi.org/10.1126/science.282.5393.1497
   PubMed Web of Science ®Google Scholar